• M-CSF and the IGF2BP1–THBS1 Fibrosis Axis

  2026-10-08

  A translational perspective on how M-CSF biology can improve interpretation of macrophage fibrosis models, informed by the 2025 IGF2BP1–THBS1–TLR4 study and the research role of an untagged recombinant mouse cytokine.

• Multiple Myeloma Cell Lines: Mutational Drivers

  2026-10-08

  Vikova and colleagues provide a broad exome-based map of mutations across 30 human multiple myeloma cell lines and connect genomic alterations with drug-response patterns. The study helps researchers select better-characterized models for hematological malignancy research while showing why cell-line findings require validation in primary tumors.

• Palonosetron and Chemotherapy-Induced Nausea and Vomiting

  2026-10-07

  Ruhlmann and Herrstedt review palonosetron as a distinctive 5-HT3 receptor antagonist, emphasizing its long half-life, high receptor affinity, allosteric binding, and positive cooperativity. The clinically important question is whether these pharmacologic features improve acute or delayed chemotherapy-induced nausea and vomiting compared with earlier agents and how palonosetron fits within combination antiemetic therapy.

• Procainamide Hydrochloride: Translational Signals

  2026-10-07

  Procainamide Hydrochloride sits at the intersection of cardiac electrophysiology, immunomodulation, epigenetic biology, and platinum-drug toxicology. This evidence-led perspective examines what the available data support, where mechanistic hypotheses remain provisional, and how translational researchers can frame the next questions without overextending preclinical findings.

• MOG (35-55) in EAE and Neuroinflammation Research

  2026-10-06

  MOG (35-55) is a research peptide used in conceptual models of autoimmune neuroinflammation, while recent work on PARP7–STAT1/STAT2 signaling provides a separate mechanistic framework for interpreting EAE outcomes. This overview distinguishes supplier-described applications from findings in a 2025 Cell Reports study, compares evidence strength, and defines the limits of translating an autoimmune encephalomyelitis model into multiple sclerosis research.

• C8-HSL and Lung Cancer Progression: Study Analysis

  2026-10-05

  A 2026 FASEB Journal study reports that the bacterial quorum-sensing molecule C8-HSL promotes proliferation, migration, and invasion in H460 lung cancer cells while engaging PI3K/AKT/ERK signaling. The findings establish a mechanistic hypothesis connecting microbial communication with tumor-cell behavior, but their relevance to human lung microbiota and clinical risk remains unconfirmed.

• LPS Protects Macrophages: System Xc− and ABCC1

  2026-10-05

  A 2026 study reports that lipopolysaccharide protects RAW264.7 macrophages from antitumor drug-induced injury while showing little comparable protection in the tested tumor-cell model. The findings connect this phenotype with SLC3A2/SLC7A11-associated system Xc− activity, glutathione maintenance, and a possible role for ABCC1-mediated transport, while also highlighting the interpretive limits of inhibitor-based evidence.

• PA-Src-FAK-RhoA/ROCK Signaling in Decidualization

  2026-10-04

  Jun and colleagues identify a phosphatidic acid–Src–FAK–RhoA/ROCK axis that links lipid signaling to cytoskeletal remodeling during human endometrial stromal cell decidualization. The study separates morphological differentiation from conventional decidual markers and provides complementary cell-based and mouse-model evidence, while leaving important questions about pathway specificity and human implantation unresolved.

• Epacadostat and IDO1: Evidence, Uses, and Limits

  2026-10-03

  Epacadostat (INCB024360) is an IDO1 inhibitor used as a mechanistic probe in immunometabolism and immuno-oncology research. This overview compares biochemical, ex vivo, preclinical, and clinical evidence, emphasizing why target potency and immune modulation do not necessarily predict benefit from a PD-1/PD-L1 checkpoint inhibitor combination.

• Ibrutinib: From BTK Mechanism to Translation

  2026-10-02

  Ibrutinib (PCI-32765) provides a mechanistically precise way to interrogate BTK-dependent B-cell biology, from B-cell receptor signaling inhibition to chronic lymphocytic leukemia research and autoimmune disease models. This translational perspective connects covalent target engagement with assay design, model selection, formulation discipline, and evidence-aware interpretation.

• N-octanoyl-L-Homoserine lactone Workflows

  2026-10-01

  Build controlled quorum-sensing, biofilm, and host-cell assays with C8-HSL while separating signaling effects from growth and solvent artifacts. The workflow also translates recent lung cancer findings into practical pathway, migration, and invasion experiments.

• Hydroxychloroquine Sulfate Workflow Guide

  2026-10-01

  Hydroxychloroquine Sulfate provides a water-compatible research reagent for studying autophagy pathway modulation and TLR7/9-dependent immune signaling in autoimmune disease research. It is suited to freshly prepared aqueous workflows, but should not be selected for DMSO- or ethanol-based stocks or long-term storage of prepared solutions.

• Measuring Drug Responses Beyond Simple Cell Viability

  2026-09-30

  Hannah R. Schwartz’s 2022 dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for separating growth inhibition from cell killing, while accounting for their different proportions and timing in vitro.

• Standardized Whole-Blood Immune Metabolism

  2026-09-30

  Zhao and colleagues introduce a standardized ex vivo whole-blood stimulation workflow for examining how metabolic interventions reshape cytokine responses to innate immune and microbial stimuli. The protocol preserves blood-based cellular interactions while improving comparability across samples, supporting cohort studies and translational immunometabolism research.

• Recombinant Human FGF-19: Assay Design for AKI

  2026-09-29

  Recombinant Human FGF-19 provides a defined ligand system for investigating FGFR4–β-Klotho signaling at the intersection of metabolic regulation and renal inflammation. This article develops a cautious, mechanism-oriented assay strategy inspired by WIP1–p38 MAPK pyroptosis research.

8514 records 1/568 page Next 12345 下5页 Last page